Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein

Journal of Virological Methods

Volumn 197, Issue , 2014, Pages 1-6

  Zhou, Chao Ming ^a   Zhang, Gao Xia ^a   Ma, Xin Xing ^a  

^a Shanghai Zerun Biotechnology Co Ltd   (China)

Author keywords

Cellular immune response; Human papillomaviruses; Humoral immune response; Immunogenicity; Therapeutic vaccine

Indexed keywords

PROTEIN E7 HEPATITIS B SURFACE ANTIGEN HEAT SHOCK PROTEIN 65 FUSION PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CAPILLARY ISOELECTRIC FOCUSING; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSTIMULATION; INTERFERON GAMMA RELEASE ASSAY; LIGHT SCATTERING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; ULTRACENTRIFUGATION; VACCINATION; WESTERN BLOTTING;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

CELLULAR IMMUNE RESPONSE; HUMAN PAPILLOMAVIRUSES; HUMORAL IMMUNE RESPONSE; IMMUNOGENICITY; THERAPEUTIC VACCINE;

ANIMALS; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEAT-SHOCK PROTEINS; HEPATITIS B CORE ANTIGENS; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC;

EID: 84890409367     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.10.033     Document Type: Article

References (32)

1. Agosti J.M., Goldie S.J. Introducing HPV vaccine in developing countries-key challenges and issues. N. Engl. J. Med. 2007, 356:1908-1910.
2. +T-cell memory and prime-boost response after dendritic-cell vaccination. Nat. Med. 2005, 11:748-756.
3. Bosch F.X., Manos M.M., Munoz N., Sherman M., Cansen A.M., Peto J. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Nat. Cancer Inst. 1995, 87:796-802.
4. Cervarix [Product Insert] GlaxoSmithKline, London, UK 2007.
5. Cho B.K., Palliser D., Guillen E., Wisniewski J., Young R.A., Chen J., Eisen H.N. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 2000, 12:263-272.
6. Chu N.R., Wu H.B., Wu T., Boux L.J., Siegel M.I., Mizzen L.A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin. Exp. Immunol. 2000, 121:216-225.
7. + T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 2005, 65:2018-2025.
8. Gardasil [Product Insert] Whitehouse Station 2006, Merck & Co. Inc., NJ, USA.
9. Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Nat. Cancer Inst. 2000, 92:709-720.
10. Granadillo M., Vallespi M.G., Batte A., Mendoza O., Soria Y., Lugo V.M., Torrens I. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice. Vaccine 2011, 29:920-930.
11. Grunbaum J.A., Kann L., Kinchen S., Ross J., Hawkins J., Lowry R., Harris W.A., McManus T., Chyen D., Collins J. Youth Risk Behavior Surveillance-United States, 2003. MMWR Surveill Summ 2004, 53. pp. 1-96.
12. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 1997, 102(5A):3-8.
13. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V., McMichael A.J. Rapid effector function in CD8(+) memory T cells. J. Exp. Med. 1997, 186:859-865.
14. Li D., Li H., Zhang P., Wu X., Wei H., Wang L., Wan M., Deng P., Zhang Y., Wang J., Liu Y., Yu Y., Wang L. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity. Eur. J. Immunol. 2006, 36:1324-1336.
15. Liu B., Ye D., Song X., Zhao X., Yi L., Song J., Zhang Z., Zhao Q. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine 2008, 26:1387-1396.
16. + memory response by heat shock fusion protein. Clin. Vaccine Immunol. 2007, 4:1013-1023.
17. Mashishi T., Gray C.M. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin. Chem. Lab. Med. 2002, 40:903-910.
18. Meneguzzi G., Cerni C., Kieny M.P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology 1991, 181:62-69.
19. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., de Sanjose S., Hammouda D., Shah K.V., Meijer C.J. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer 2004, 111:278-285.
20. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., Slansky J., Ahmed R. Counting antigen-specific CD8T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8:177-187.
21. Schmittel A., Keilholz U., Scheibenbogen C. Evaluation of the interferongamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood. J. Immunol. Methods 1997, 210:167-174.
22. Sewell D.A., Pan Z.K., Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 2008, 26:5315-5320.
23. Street M.D., Tindle R.W. Vaccines for human papillomavirus-associated anogenital disease and cervical cancer: practical and theoretical approaches. Expert Opin. Invest. Drugs 1999, 8:761-776.
24. Sun Y., Iglesias E., Samri A., Kamkamidze G., Decoville T., Carcelain G., Autran B. A systematic comparison of methods to measure HIV-1 specific CD8T cells. J. Immunol. Methods 2003, 272:23-34.
25. Tomatis L. Cancer, Cause Occurrence and Control 1990, World Heath Organization, International Agency for Research on Cancer, Lyon.
26. + T cells to antigen stimulation in vivo. Nat. Immunol. 2000, 1:47-53.
27. Wang H., Su X., Zhang P., Liang J., Wei H., Wan M., Wu X., Yu Y., Wang L. Recombinant heat shock protein 65 carrying PADRE and HBV epitopes activates dendritic cells and elicits HBV-specific CTL responses. Vaccine 2011, 29:2328-2335.
28. + T cells in vivo. J. Immunol. 2002, 169:5622-5629.
29. Yan J., Reichenbach D.K., Corbitt N., Hokey D.A., Ramanathan M.P., McKinney K.A., Weiner D.B., Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine 2009, 27:431-440.
30. Yang B.F., Zhao H.L., Xue C., Xiong X.H., Zhang W., Yao X.Q., Liu Z.M. Recombinant heat shock protein 65 carrying hepatitis B core antigen induces HBcAg-specific CTL response. Vaccine 2007, 25:4478-4486.
31. Zhou C.M. Characterization of human papillomavirus by capillary isoelectric focusing with whole-column imaging detection. Electrophoresis 2013, 34:3046-3053.
32. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2002, 2:342-350.